Retartrutide Specifications:
Company: Hilma Biocare
Retartrutide (LY-3437943) is a medication indicated for the treatment of obesity. It is a triple agonist of GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor) receptors. Retartrutide is a 39-amino acid peptide resistant to cleavage by DPP4, the enzyme that cleaves GLP-1 and GIP. Retartrutide is constructed from a GIP peptide structure to achieve triple agonist activity against GLP-1R, GIP, and GCGR.
Indication:
Treatment of type 2 diabetes mellitus and weight loss. Retartrudide is used to improve glycemic control in combination with diet and exercise.
Mechanism of action
: Retartrudide exerts its therapeutic effect through several mechanisms.
The medication mimics the GLP-1 hormone, which is naturally released after a meal. This hormone sends a satiety signal to the brain, helping to reduce appetite and prevent overeating. Thus, Retatrutide's first mechanism of action is to promote a longer feeling of fullness.
As a GLP-1 and GCGR agonist, Retatrutide increases insulin release from the pancreas while simultaneously reducing glucagon release, leading to increased blood sugar levels and stabilization of energy levels. The second mechanism can be described as stimulation of metabolism: the use of energy obtained from food for vital bodily processes, instead of storing it as fat. This process ultimately leads to weight loss and can help lower blood pressure.
Retatrutide prevents sharp drops in blood sugar levels, which often lead to food cravings and/or irregular eating habits, ultimately resulting in overeating. This effect can make it easier to stick to a weight loss plan and monitor your diet.
Clinical studies have shown that Retatrutide can lead to weight loss in just 4 weeks. Results from clinical trials demonstrate that, in obese or overweight adults (non-diabetic) treated with Retatrutide, body weight loss can reach 15-35% after completion of treatment.
Protection code:
How it works: Hilma Biocare™
prioritizes
consumer safety and regularly develops various protective measures for its products, ensuring patient safety and confidence in our products.
Retartrutide Specifications:
Company: Hilma Biocare
Retartrutide (LY-3437943) is a medication indicated for the treatment of obesity. It is a triple agonist of GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor) receptors. Retartrutide is a 39-amino acid peptide resistant to cleavage by DPP4, the enzyme that cleaves GLP-1 and GIP. Retartrutide is constructed from a GIP peptide structure to achieve triple agonist activity against GLP-1R, GIP, and GCGR.
Indication:
Treatment of type 2 diabetes mellitus and weight loss. Retartrudide is used to improve glycemic control in combination with diet and exercise.
Mechanism of action
: Retartrudide exerts its therapeutic effect through several mechanisms.
The medication mimics the GLP-1 hormone, which is naturally released after a meal. This hormone sends a satiety signal to the brain, helping to reduce appetite and prevent overeating. Thus, Retatrutide's first mechanism of action is to promote a longer feeling of fullness.
As a GLP-1 and GCGR agonist, Retatrutide increases insulin release from the pancreas while simultaneously reducing glucagon release, leading to increased blood sugar levels and stabilization of energy levels. The second mechanism can be described as stimulation of metabolism: the use of energy obtained from food for vital bodily processes, instead of storing it as fat. This process ultimately leads to weight loss and can help lower blood pressure.
Retatrutide prevents sharp drops in blood sugar levels, which often lead to food cravings and/or irregular eating habits, ultimately resulting in overeating. This effect can make it easier to stick to a weight loss plan and monitor your diet.
Clinical studies have shown that Retatrutide can lead to weight loss in just 4 weeks. Results from clinical trials demonstrate that, in obese or overweight adults (non-diabetic) treated with Retatrutide, body weight loss can reach 15-35% after completion of treatment.
Protection code:
How it works: Hilma Biocare™
prioritizes
consumer safety and regularly develops various protective measures for its products, ensuring patient safety and confidence in our products.